【環(huán)球熱聞】合全藥業(yè)與英矽智能達(dá)成戰(zhàn)略合作

左起依次為：英矽智能聯(lián)席首席執(zhí)行官、首席科學(xué)官任峰博士，藥明康德高級(jí)副總裁、合全藥業(yè)原料藥業(yè)務(wù)部負(fù)責(zé)人傅小勇博士

中國上海，2022年9月1日 -- 藥明康德子公司合全藥業(yè)與端到端人工智能驅(qū)動(dòng)的藥物研發(fā)公司英矽智能（Insilico Medicine）共同宣布，針對(duì)一體化CMC服務(wù)簽署戰(zhàn)略合作協(xié)議。英矽智能聯(lián)席首席執(zhí)行官、首席科學(xué)官任峰博士，藥明康德高級(jí)副總裁、合全藥業(yè)原料藥業(yè)務(wù)部負(fù)責(zé)人傅小勇博士，合全藥業(yè)高級(jí)副總裁、制劑業(yè)務(wù)負(fù)責(zé)人陳金玲博士等共同出席了簽約儀式。

英矽智能是一家由端到端人工智能（AI）驅(qū)動(dòng)的藥物研發(fā)公司，管線覆蓋癌癥、纖維化、免疫、中樞神經(jīng)系統(tǒng)疾病以及衰老相關(guān)疾病等領(lǐng)域，已開發(fā)超30條自研管線。其中進(jìn)展最快的抗纖維化項(xiàng)目ISM001-055目前正在新西蘭和中國同步開展1期臨床試驗(yàn)。公司于2021年與合全藥業(yè)展開合作，合全藥業(yè)為其抗纖維化項(xiàng)目提供了原料藥及制劑的研發(fā)和生產(chǎn)端到端支持。

(資料圖片僅供參考)

合全藥業(yè)作為CRDMO領(lǐng)軍企業(yè)，2017年以來已成功支持合作伙伴的35款創(chuàng)新藥獲批，支持的新藥在全球105個(gè)國家上市。此次英矽智能與合全藥業(yè)簽署戰(zhàn)略合作協(xié)議，是在ISM001-055成功合作的基礎(chǔ)上，進(jìn)一步拓展雙方合作的深度和寬度。根據(jù)戰(zhàn)略合作協(xié)議，合全藥業(yè)將成為英矽智能在新藥合同研究、開發(fā)與生產(chǎn)領(lǐng)域（CRDMO）的首選合作伙伴，為其在研及后續(xù)管線產(chǎn)品提供原料藥及制劑產(chǎn)品的研究、工藝開發(fā)、生產(chǎn)、分析以及支持新藥申報(bào)的注冊(cè)文件準(zhǔn)備等一站式服務(wù)。

“我們非常高興借助合全藥業(yè)端到端CMC平臺(tái)加快項(xiàng)目進(jìn)度，雙方過去的合作卓有成效?！?strong>英矽智能創(chuàng)始人兼首席執(zhí)行官Alex Zhavoronkov博士表示：”相信此次深化合作，將幫助我們進(jìn)一步提升藥物開發(fā)的速度和效率，早日滿足迫切的臨床醫(yī)療需求?！?/p>

“很高興與英矽智能強(qiáng)化合作關(guān)系?！?strong>藥明康德聯(lián)席首席執(zhí)行官、合全藥業(yè)首席執(zhí)行官陳民章博士表示：“合全藥業(yè)將繼續(xù)提升一體化CRDMO平臺(tái)能力，更好地賦能合作伙伴加速創(chuàng)新藥開發(fā)，惠及全球病患?！?/p>

關(guān)于合全藥業(yè)

合全藥業(yè)是藥明康德子公司，在亞洲、北美及歐洲地區(qū)均設(shè)有研發(fā)及生產(chǎn)基地。合全藥業(yè)服務(wù)于生命科學(xué)行業(yè)，擁有卓越的化學(xué)創(chuàng)新藥研發(fā)和生產(chǎn)的能力和技術(shù)平臺(tái)。作為全球新藥合同研究、開發(fā)與生產(chǎn)領(lǐng)域（CRDMO）的領(lǐng)軍企業(yè)，合全藥業(yè)致力于為全球合作伙伴提供高效、靈活、高質(zhì)量的一站式解決方案，以支持包括小分子、寡核苷酸、多肽及各種復(fù)雜化學(xué)偶聯(lián)藥物的研發(fā)與生產(chǎn)。更多信息，請(qǐng)?jiān)L問公司網(wǎng)站：www.stapharma.com.cn

WuXi STA Forms Strategic Partnership with Insilico Medicine

From left to right: Insilico Medicine co-CEO and Chief Scientific Officer Dr. Feng Ren, WuXi AppTec Senior Vice President and WuXi STA API Business Head Dr. Xiaoyong Fu

SHANGHAI, CHINA, September 1, 2022 – WuXi STA, a subsidiary of WuXi AppTec, and Insilico Medicine, a global clinical-stage artificial intelligence-driven drug discovery and development company, today announced a strategic partnership for the integrated CMC services.

Insilico Medicine owned more than 30 pipelines under development, covering various diseases, including cancers, fibrosis, immunity, central nervous system diseases, and aging-associated diseases. Insilico’s leading anti-fibrosis drug candidate, ISM001-055, is undergoing phase 1 clinical trials in both New Zealand and China. The collaboration between WuXi STA and Insilico started in 2021, while WuXi STA provided the end-to-end CMC service, including both API and formulation development and manufacturing for ISM001-055.

As the leading CRDMO, WuXi STA has supported 35 new drugs approved globally since 2017, and the products manufactured have been launched in 105 countries. This strategic partnership is to broaden the collaboration between WuXi STA and Insilico beyond ISM001-055. Under this agreement, WuXi STA will be the preferred contract research, development, and manufacturing organization (CRDMO) partner and will provide integrated end-to-end CMC solutions to Insilico’s current and future drug discovery and development projects. The services include but are not limited to API and drug product research, development, manufacturing, and regulatory CMC dossier preparation services.

Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine, commented:“We are excited to have WuXi STA’s end-to-end CMC platform supporting our projects. The past collaboration was fruitful, and I believe this collaboration expansion will greatly accelerate our pipelines to the market and fulfill the patients’ demand around the world.”

Dr. Minzhang Chen, co-CEO of WuXi AppTec and CEO of WuXi STA, commented:“We are pleased to enhance our partnership with Insilico. We will continue building our integrated CRDMO platform and look forward to empowering more breakthroughs to benefit patients worldwide.”

About WuXi STA

WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate.

For more information, please visit: http://www.STApharma.com

About Insilico Medicine

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.

For more information, visit www.insilico.com

關(guān)鍵詞： 合全藥業(yè)與英矽智能達(dá)成戰(zhàn)略合作 合全藥業(yè) insilico medi